Structure-based selectivity optimization of piperidine-pteridine derivatives as potent Leishmania pteridine reductase inhibitors.
暂无分享,去创建一个
A. Cavalli | P. Michels | V. Hannaert | P. Corona | A. Carta | E. Nerini | P. Saxena | Shreedhara Gupta | R. Luciani | S. Ferrari | Davide Guerrieri | M. Loriga | G. Paglietti | P. M. Costi | Federica Gibellini
[1] M. Day,et al. One Health: The global challenge of epidemic and endemic leishmaniasis , 2011, Parasites & Vectors.
[2] Maria Paola Costi,et al. Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase. , 2011, Journal of medicinal chemistry.
[3] A. Fairlamb,et al. Trypanosoma brucei pteridine reductase 1 is essential for survival in vitro and for virulence in mice , 2010, Molecular microbiology.
[4] P. Ready. Leishmaniasis emergence in Europe. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[5] N. Schormann,et al. Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate. , 2009, Acta crystallographica. Section D, Biological crystallography.
[6] Maria Paola Costi,et al. Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development , 2008, Proceedings of the National Academy of Sciences.
[7] Ting-Chao Chou,et al. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.
[8] K. Stengele,et al. New Types of Very Efficient Photolabile Protecting Groups Based upon the [2-(2-Nitrophenyl)propoxy]carbonyl (NPPOC) Moiety , 2004 .
[9] S. Beverley,et al. Pteridine salvage throughout the Leishmania infectious cycle: implications for antifolate chemotherapy. , 2001, Molecular and biochemical parasitology.
[10] David S. Goodsell,et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..
[11] Ian H. Gilbert,et al. Dihydrofolate reductase: A potential drug target in trypanosomes and leishmania , 1998, J. Comput. Aided Mol. Des..
[12] David A. Matthews,et al. Structure of and kinetic channelling in bifunctional dihydrofolate reductase–thymidylate synthase , 1994, Nature Structural Biology.
[13] M. Ouellette,et al. A novel antifolate resistance gene on the amplified H circle of Leishmania. , 1992, The EMBO journal.
[14] T. Harris,et al. Synthesis of DL-slaframine , 1984 .
[15] R. Brun,et al. Cultivation and in vitro cloning or procyclic culture forms of Trypanosoma brucei in a semi-defined medium. Short communication. , 1979, Acta tropica.
[16] J. Montgomery,et al. Preparation of 6-(bromomethyl)-2,4-pteridinediamine hydrobromide and its use in improved syntheses of methotrexate and related compounds. , 1977, The Journal of organic chemistry.
[17] I. H. Segel. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems , 1975 .
[18] R. Riemschneider,et al. Acylderivate cyclischer Verbindungen, V. Zur Herstellung von o‐Diacetyl‐benzol und 4‐Nitro‐1.2‐diacetyl‐benzol , 1959 .
[19] D Steverding,et al. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. , 2000, Parasitology international.